Boston, MA – June 5, 2026 – Rezolute, Inc. (NASDAQ: RZLT), a biopharmaceutical company focused on developing innovative therapies for rare diseases, is experiencing a significant resurgence in its stock value following encouraging interim data from its second Phase III clinical trial of ersodetug. The investigational fully human monoclonal antibody (mAb) is being evaluated for its efficacy in treating tumour-induced hyperinsulinism (HI), a rare and often debilitating condition. The positive developments have seen the company’s stock climb, signaling renewed investor confidence after a previous setback.
The current trial (NCT06881992), which is open-label, has enrolled 16 patients with tumour HI. To date, eight patients have received ersodetug, with a remarkable six of them meeting the study’s primary endpoint. This endpoint is defined by achieving at least a 50% reduction from baseline in intravenous glucose requirements (glucose infusion rate; GIR) within eight weeks of treatment. Crucially, all six responders have also achieved complete discontinuation of their reliance on intravenous glucose.
This promising efficacy data, particularly the complete cessation of glucose infusion in a majority of treated patients, has propelled Rezolute’s stock upwards by over 10% in early June. This positive market reaction contrasts sharply with the significant downturn experienced after the company announced initial data from its first Phase III trial. The company is now focused on the ongoing enrollment and treatment phases, with topline results for this pivotal study anticipated in the latter half of 2026.
Promising Efficacy in Tumour Hyperinsulinism: A Beacon of Hope
Tumour-induced hyperinsulinism is a complex and rare endocrine disorder characterized by excessive insulin secretion from pancreatic islet cell tumors (ICTs) or, less commonly, non-islet cell tumors (NICTs). This overproduction of insulin leads to recurrent and severe hypoglycemia, characterized by dangerously low blood sugar levels. Patients often suffer from a spectrum of debilitating symptoms, including confusion, seizures, loss of consciousness, and in severe cases, irreversible neurological damage or even death. Management typically involves frequent meals, glucose infusions, and in some instances, surgical intervention, which is not always feasible or effective.
The current Phase III trial for ersodetug in tumour HI is designed to rigorously assess the drug’s ability to alleviate the glucose-dependency of these patients. The primary endpoint, measuring a substantial reduction in GIR, directly correlates with the severity of the condition and the patient’s need for external glucose support. The achievement of this endpoint in six out of eight treated patients, with all six discontinuing intravenous glucose, represents a significant clinical milestone.
Dr. Brian Roberts, Chief Medical Officer of Rezolute, expressed optimism about the emerging data. "These results reveal the clinically impactful hypoglycaemia-correcting activity of ersodetug in an unbiased GIR assessment in patients with HI caused by varying tumour types," Dr. Roberts stated. "This further highlights the aberrant outcome from the recently completed randomised, placebo-controlled, Phase III sunRIZE study in paediatric congenital HI, where we believe that self-monitored glycaemic measures were confounded by divergent caretaker behaviours stemming from functional unblinding to treatment status by real-time glucose monitoring."
This statement from Dr. Roberts is particularly significant as it directly addresses the company’s previous challenges and attempts to contextualize the current positive findings within a broader understanding of their clinical development strategy.
Navigating the Clinical Trial Landscape: A Chronological Perspective
Rezolute’s journey with ersodetug has been marked by both significant progress and challenging setbacks. Understanding the timeline of events is crucial to appreciating the current positive momentum.
-
December 2025: Rezolute announced that its Phase III sunRIZE study (NCT06208215) for paediatric congenital hyperinsulinism failed to meet its primary or key secondary endpoints. This news had a dramatic impact on the company’s stock, which plummeted by 88.75%, falling from a closing price of $10.94 on December 10th to an opening of $1.23 on December 11th. The stock eventually closed at $1.40 on the same day, reflecting a significant loss of investor confidence. The company attributed the outcome in the sunRIZE trial to potential confounds in glycemic monitoring, suggesting that real-time glucose monitoring may have led to functional unblinding of caregivers, thereby influencing their behavior and potentially skewing the results.
-
Early 2026: Despite the setback with the sunRIZE trial, Rezolute continued its development program for ersodetug, shifting focus to the ongoing Phase III trial in tumour-induced hyperinsulinism. This trial, designed as an open-label study, was initiated to explore ersodetug’s efficacy in a different patient population with a distinct etiology of hyperinsulinism.
-
Present (June 2026): The company announced interim data from the tumour HI trial, revealing that eight out of 16 planned patients have been treated. Of these, six have met the primary endpoint, demonstrating a significant reduction in glucose infusion rates and, in all six cases, a complete discontinuation of intravenous glucose. This positive news has led to a substantial increase in Rezolute’s stock price.
The current trial’s open-label design allows for more direct observation of ersodetug’s effects without the potential blinding issues that Rezolute believes may have impacted the previous study. This approach, while potentially subject to observer bias, provides valuable insights into the drug’s efficacy and tolerability in a specific patient group.
Supporting Data: Quantifying the Impact of Ersodetug
The interim data from the tumour HI trial provides concrete metrics for ersodetug’s performance:
- Patient Enrollment: 16 patients planned, 8 treated to date.
- Primary Endpoint Achievement: 6 out of 8 treated patients met the responder criteria.
- Responder Criteria: At least a 50% reduction from baseline in intravenous glucose requirements (GIR) within eight weeks.
- Glucose Discontinuation: All six responders achieved complete discontinuation of intravenous glucose.
- Patient Withdrawal: One patient withdrew consent due to advanced cancer (Stage 4 metastatic colon cancer with ECOG 4 performance status) and opted for hospice care, subsequently passing away from cancer progression. This case is considered outside the scope of ersodetug’s efficacy assessment due to the patient’s critical condition and withdrawal from active treatment.
- Ongoing Treatment: The final patient has been enrolled and is currently in the pivotal treatment phase.
- Open-Label Extension: All six completers have opted to continue into the open-label extension phase, aiming for a cumulative treatment duration of up to six months.
- Safety Profile: Ersodetug has demonstrated a favorable safety profile, with no drug-related adverse events or significant safety findings reported to date in either the pivotal or extension phases of the study.
The stock market’s reaction underscores the significance of these findings. Rezolute’s stock, traded on the Nasdaq, rose 10.8% on June 2nd, climbing from a June 1st close of $3.61 to a June 2nd close of $4.00. Pre-market trading on June 5th indicated a further estimated increase of 9.25%, reflecting sustained investor optimism.
Official Responses and Strategic Outlook
The encouraging interim results have prompted enthusiastic responses from Rezolute’s leadership. Dr. Brian Roberts’ statement highlights the perceived clinical impact and provides a rationale for the current findings, contrasting them with the previous study’s outcome. This strategic communication aims to rebuild confidence in ersodetug’s potential and Rezolute’s development capabilities.
Rezolute has indicated its intention to continue engaging with the U.S. Food and Drug Administration (FDA) regarding the development of ersodetug. The FDA’s guidance will be critical in determining the path forward for potential regulatory approval. The company’s commitment to advancing ersodetug, even after the sunRIZE trial’s failure, demonstrates their belief in the drug’s therapeutic value, particularly in specific patient populations.
The company anticipates the topline results of the open-label tumour HI study in the second half of 2026. This timeline is crucial for investors and stakeholders who are closely watching the development of Rezolute’s sole pipeline candidate. The success of this trial could significantly alter the company’s trajectory and provide a much-needed therapeutic option for patients suffering from tumour-induced hyperinsulinism.
Implications for Patients and the Pharmaceutical Landscape
The potential success of ersodetug in treating tumour-induced hyperinsulinism carries profound implications for patients and the broader pharmaceutical landscape.
For Patients: If approved, ersodetug could offer a life-changing treatment for individuals suffering from tumour HI. The ability to reduce or eliminate the need for continuous intravenous glucose infusions would significantly improve patients’ quality of life, allowing for greater independence and mobility. The current data suggesting complete discontinuation of IV glucose in responders is particularly compelling. Furthermore, a favorable safety profile would make it an attractive alternative to more invasive or less effective management strategies.
For Rezolute: This trial’s success is pivotal for Rezolute’s future. A positive outcome could validate the company’s scientific approach and provide a much-needed commercial product. It would also allow Rezolute to recover from the significant financial and reputational damage caused by the sunRIZE trial failure. The renewed investor confidence, reflected in the stock price surge, provides a more stable financial footing for continued development and potential commercialization efforts.
For the Pharmaceutical Industry: The development of targeted therapies for rare diseases like tumour HI is a growing area of focus. Ersodetug’s mechanism as a monoclonal antibody targeting the insulin receptor pathway represents a sophisticated approach to a complex endocrine disorder. If successful, it could pave the way for similar targeted therapies in other rare metabolic conditions. The debate surrounding the interpretation of clinical trial data, particularly in trials with potential for unblinding, also serves as a valuable lesson for the industry, emphasizing the importance of robust trial design and objective endpoints.
While challenges remain, including the completion of the current trial and regulatory review, the interim results for ersodetug in tumour hyperinsulinism represent a significant step forward. Rezolute’s ability to pivot and demonstrate promising results in a different patient population highlights the resilience of their development program and offers a renewed sense of hope for patients awaiting effective treatment options. The coming months will be critical as the company moves towards reporting final data and engaging with regulatory bodies.
About the Author
